# A Study to Assess Long-term Safety of Fezolinetant Given to Japanese Women Going Through Menopause

> **NCT06206421** · PHASE3 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 277 (actual)

## Conditions studied

- Hot Flashes

## Interventions

- **DRUG:** Fezolinetant
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06206421
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-02-22
- **Primary completion:** 2026-03-19
- **Final completion:** 2026-03-19
- **Target enrollment:** 277 (ACTUAL)
- **Last updated:** 2026-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06206421

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06206421, "A Study to Assess Long-term Safety of Fezolinetant Given to Japanese Women Going Through Menopause". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06206421. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*